Michael Yu, Innovent CEO (Anthony Kwan/Bloomberg via Getty Images)
China approves BCMA CAR-T therapy for multiple myeloma, with Innovent beating Legend in race to be first
Innovent and IASO Bio received the first approval in China for a CAR-T therapy for multiple myeloma.
The therapy, known as equecabtagene autoleucel, will be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.